Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trialsTumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

J.P. Banga; J.A. Gilbert; Fassi D. El; L. Hegedus; Claus Henrik Nielsen

Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trialsTumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

J.P. Banga, J.A. Gilbert, Fassi D. El, L. Hegedus, Claus Henrik Nielsen

Department of Clinical Medicine

Abstract

Most current approaches for treating Graves' disease are based essentially upon regimes developed nearly 50 years ago. Moreover, therapeutic approaches for complications such as thyroid-associated ophthalmopathy (TAO) and dermopathy are singularly dependent on conventional approaches of nonspecific immunosuppression. The recent development of an induced model of experimental Graves' disease, although incomplete as it lacks the extrathyroidal manifestations, provided opportunities to investigate immune intervention strategies, including influence upon the autoreactive B and T cell players in the autoimmune process. These major advances are generating new possibilities for therapeutic interventions for patients with Graves' disease and TAO
Udgivelsesdato: 2008/9

Original language	English
Journal	Thyroid
Volume	18
Issue number	9
Pages (from-to)	973-981
Number of pages	8
ISSN	1050-7256
Publication status	Published - 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Banga, J. P., Gilbert, J. A., El, F. D., Hegedus, L., & Nielsen, C. H. (2008). Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trialsTumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Thyroid, 18(9), 973-981.

Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trialsTumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. / Banga, J.P.; Gilbert, J.A.; El, Fassi D. et al.

In: Thyroid, Vol. 18, No. 9, 2008, p. 973-981.

Research output: Contribution to journal › Journal article › Research › peer-review

Banga, JP, Gilbert, JA, El, FD, Hegedus, L & Nielsen, CH 2008, 'Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trialsTumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease', Thyroid, vol. 18, no. 9, pp. 973-981.

Banga JP, Gilbert JA, El FD, Hegedus L, Nielsen CH. Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trialsTumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Thyroid. 2008;18(9):973-981.

Banga, J.P. ; Gilbert, J.A. ; El, Fassi D. et al. / Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trialsTumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. In: Thyroid. 2008 ; Vol. 18, No. 9. pp. 973-981.

@article{a09be9a0979411de8bc9000ea68e967b,

title = "Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trialsTumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease",

abstract = "Most current approaches for treating Graves' disease are based essentially upon regimes developed nearly 50 years ago. Moreover, therapeutic approaches for complications such as thyroid-associated ophthalmopathy (TAO) and dermopathy are singularly dependent on conventional approaches of nonspecific immunosuppression. The recent development of an induced model of experimental Graves' disease, although incomplete as it lacks the extrathyroidal manifestations, provided opportunities to investigate immune intervention strategies, including influence upon the autoreactive B and T cell players in the autoimmune process. These major advances are generating new possibilities for therapeutic interventions for patients with Graves' disease and TAO Udgivelsesdato: 2008/9",

author = "J.P. Banga and J.A. Gilbert and El, {Fassi D.} and L. Hegedus and Nielsen, {Claus Henrik}",

year = "2008",

language = "English",

volume = "18",

pages = "973--981",

journal = "Thyroid",

issn = "1050-7256",

publisher = "Mary AnnLiebert, Inc. Publishers",

number = "9",

}

TY - JOUR

T1 - Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trialsTumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

AU - Banga, J.P.

AU - Gilbert, J.A.

AU - El, Fassi D.

AU - Hegedus, L.

AU - Nielsen, Claus Henrik

PY - 2008

Y1 - 2008

N2 - Most current approaches for treating Graves' disease are based essentially upon regimes developed nearly 50 years ago. Moreover, therapeutic approaches for complications such as thyroid-associated ophthalmopathy (TAO) and dermopathy are singularly dependent on conventional approaches of nonspecific immunosuppression. The recent development of an induced model of experimental Graves' disease, although incomplete as it lacks the extrathyroidal manifestations, provided opportunities to investigate immune intervention strategies, including influence upon the autoreactive B and T cell players in the autoimmune process. These major advances are generating new possibilities for therapeutic interventions for patients with Graves' disease and TAO Udgivelsesdato: 2008/9

AB - Most current approaches for treating Graves' disease are based essentially upon regimes developed nearly 50 years ago. Moreover, therapeutic approaches for complications such as thyroid-associated ophthalmopathy (TAO) and dermopathy are singularly dependent on conventional approaches of nonspecific immunosuppression. The recent development of an induced model of experimental Graves' disease, although incomplete as it lacks the extrathyroidal manifestations, provided opportunities to investigate immune intervention strategies, including influence upon the autoreactive B and T cell players in the autoimmune process. These major advances are generating new possibilities for therapeutic interventions for patients with Graves' disease and TAO Udgivelsesdato: 2008/9

M3 - Journal article

SN - 1050-7256

VL - 18

SP - 973

EP - 981

JO - Thyroid

JF - Thyroid

IS - 9

ER -